Effect measures for comparing paired event times
By: Merle Munko , Simon Mack , Marc Ditzhaus and more
The progression-free survival ratio (PFSr) is a widely used measure in personalized oncology trials. It evaluates the effectiveness of treatment by comparing two consecutive event times - one under standard therapy and one under an experimental treatment. However, most proposed tests based on the PFSr cannot control the nominal type I error rate, even under mild assumptions such as random right-censoring. Consequently the results of these tests are often unreliable. As a remedy, we propose to estimate the relevant probabilities related to the PFSr by adapting recently developed methodology for the relative treatment effect between paired event times. As an additional alternative, we develop inference procedures based on differences and ratios of restricted mean survival times. An extensive simulation study confirms that the proposed novel methodology provides reliable inference, whereas previously proposed techniques break down in many realistic settings. The utility of our methods is further illustrated through an analysis of real data from a molecularly aided tumor trial.
Similar Papers
Exhausting the type I error level in event-driven group-sequential designs with a closed testing procedure for progression-free and overall survival
Methodology
Helps find cancer drugs faster and more reliably.
Adaptive clinical trial design with delayed treatment effects using elicited prior distributions
Methodology
Helps find cancer drugs that work slowly.
Confirmatory Adaptive Hypothesis Tests in Markovian Illness-Death Models
Methodology
Tests drug success faster using more patient info.